Frontage Announces Expansion of Business in Canada with New Leadership
Frontage Holdings Corporation (OTC:FTHCY) has announced the appointment of Dr. Abdul Mutlib as President of Frontage Laboratories, Canada, marking a strategic expansion of its services in the Canadian market. Dr. Mutlib, who will continue his role as Chief Scientific & Strategy Officer, will oversee operations in Toronto and Vancouver, reporting to Co-CEO Dr. Wentao Zhang.
With over 35 years of R&D experience in pharmaceutical and CRO sectors, Dr. Mutlib will focus on establishing Frontage as a key partner for Canada's growing biotech industry. The appointment aligns with Frontage's strategy to enhance its position as a leading global pharmaceutical Contract Research Organization (CRO).
Frontage Holdings Corporation (OTC:FTHCY) ha annunciato la nomina del Dott. Abdul Mutlib a Presidente di Frontage Laboratories, Canada, segnando un'espansione strategica dei suoi servizi nel mercato canadese. Il Dott. Mutlib, che manterr脿 il suo ruolo di Chief Scientific & Strategy Officer, supervisioner脿 le operazioni di Toronto e Vancouver, riportando direttamente al Co-CEO Dott. Wentao Zhang.
Con oltre 35 anni di esperienza in R&D nei settori farmaceutico e CRO, il Dott. Mutlib si concentrer脿 nel consolidare Frontage come partner chiave per l'industria biotecnologica canadese in crescita. Questa nomina 猫 in linea con la strategia di Frontage di rafforzare la propria posizione come una delle principali Contract Research Organization (CRO) farmaceutiche a livello globale.
Frontage Holdings Corporation (OTC:FTHCY) ha anunciado el nombramiento del Dr. Abdul Mutlib como Presidente de Frontage Laboratories, Canad谩, marcando una expansi贸n estrat茅gica de sus servicios en el mercado canadiense. El Dr. Mutlib, quien continuar谩 en su rol de Chief Scientific & Strategy Officer, supervisar谩 las operaciones en Toronto y Vancouver, reportando al Co-CEO Dr. Wentao Zhang.
Con m谩s de 35 a帽os de experiencia en I+D en los sectores farmac茅utico y CRO, el Dr. Mutlib se enfocar谩 en posicionar a Frontage como un socio clave para la creciente industria biotecnol贸gica de Canad谩. El nombramiento est谩 alineado con la estrategia de Frontage para fortalecer su posici贸n como una organizaci贸n l铆der global de investigaci贸n por contrato farmac茅utica (CRO).
Frontage Holdings Corporation (OTC:FTHCY)电� Dr. Abdul Mutlib毳� Frontage Laboratories 旌愲倶雼� 歆�靷潣 靷灔鞙茧 鞛勲獏頄堧嫟瓿� 氚滍憸頃橂┌, 旌愲倶雼� 鞁滌灔鞐愳劀 靹滊箘鞀れ潣 鞝勲灥鞝� 頇曥灔鞚� 鞎岆牳鞀惦媹雼�. Mutlib 氚曥偓电� Chief Scientific & Strategy Officer 鞐暊鞚� 瓿勳啀 靾橅枆頃橂┐靹� 韱犽韱犾檧 氚挫繝氩�鞚� 鞖挫榿鞚� 齑濌磩頃橂┌ 瓿惦彊 CEO鞚� Dr. Wentao Zhang鞐愱矊 氤搓碃頃� 鞓堨爼鞛呺媹雼�.
鞝滌暯 氚� CRO 攵勳暭鞐愳劀 35雲� 鞚挫儊鞚� 鞐瓣惮臧滊皽 瓴巾棙鞚� 臧�歆� Mutlib 氚曥偓电� 旌愲倶雼れ潣 靹膘灔頃樀鐢 氚旍澊鞓ろ厤 靷办梾鞐愳劀 Frontage毳� 頃奠嫭 韺岉姼雱堧 鞛愲Μ毵り箑頃樀鐢 雿� 歆戩頃� 瓴冹瀰雼堧嫟. 鞚措矆 鞛勲獏鞚� Frontage臧� 旮�搿滊矊 靹犽弰 鞝滌暯 瓿勳暯 鞐瓣惮旮瓣磤(CRO)鞙茧靹滌潣 鞛呾毳� 臧曧檾頃橂牑电� 鞝勲灥瓿� 鞚检箻頃╇媹雼�.
Frontage Holdings Corporation (OTC:FTHCY) a annonc茅 la nomination du Dr Abdul Mutlib en tant que pr茅sident de Frontage Laboratories Canada, marquant une expansion strat茅gique de ses services sur le march茅 canadien. Le Dr Mutlib, qui conservera son r么le de Chief Scientific & Strategy Officer, supervisera les op茅rations 脿 Toronto et Vancouver, sous la direction du co-CEO Dr Wentao Zhang.
Fort de plus de 35 ans d鈥檈xp茅rience en R&D dans les secteurs pharmaceutique et CRO, le Dr Mutlib se concentrera sur l鈥櫭﹖ablissement de Frontage comme partenaire cl茅 de l鈥檌ndustrie biotechnologique canadienne en pleine croissance. Cette nomination s鈥檌nscrit dans la strat茅gie de Frontage visant 脿 renforcer sa position de leader mondial des organisations de recherche sous contrat (CRO) pharmaceutiques.
Frontage Holdings Corporation (OTC:FTHCY) hat die Ernennung von Dr. Abdul Mutlib zum Pr盲sidenten von Frontage Laboratories Kanada bekannt gegeben, was eine strategische Erweiterung der Dienstleistungen auf dem kanadischen Markt markiert. Dr. Mutlib, der weiterhin seine Rolle als Chief Scientific & Strategy Officer aus眉ben wird, 眉bernimmt die Leitung der Standorte in Toronto und Vancouver und berichtet an den Co-CEO Dr. Wentao Zhang.
Mit 眉ber 35 Jahren Erfahrung in Forschung und Entwicklung in der Pharma- und CRO-Branche wird Dr. Mutlib sich darauf konzentrieren, Frontage als wichtigen Partner f眉r die wachsende Biotech-Industrie Kanadas zu etablieren. Die Ernennung entspricht der Strategie von Frontage, seine Position als f眉hrende globale Contract Research Organization (CRO) im Pharmabereich zu st盲rken.
- Expansion into Canadian market with operations in Toronto and Vancouver
- Appointment of experienced leader with 35+ years of R&D expertise
- Strategic positioning to serve growing Canadian biotech industry
- None.
Dr. Mutlib brings more than 35 years of R&D experience in large pharmaceutical and CRO and will play a key role in establishing Frontage as a key partner and service provider to the rapidly growing biotech industry across
Dr. Zhang commented, "Abdul's leadership and experience has been vital to Frontage's growth over the last several years. His vision and strong leadership qualities will drive our success and expansion in
Dr. Mutlib expressed, "I'm deeply honored by this opportunity. I have full confidence in our Canadian team, and together, we aim to expand our services and significantly grow the business in the coming years. I'm excited to collaborate with Canadian authorities and establish Frontage as a leading provider of comprehensive, high-quality R&D services, supporting
About Frontage ()
Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiaries, including Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) that provides integrated, science-driven, product development services from drug discovery to late-phase clinical process to enable biopharmaceutical companies to achieve their development goals.鈥疌omprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety鈥痑nd toxicology assessment, and early-phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions.鈥燜or more details visit .
Media Contact:
Xiaoyun Niu
[email protected]
(610) 232-0100
View original content to download multimedia:
SOURCE Frontage Laboratories, Inc.
FAQ
Who is the new President of Frontage Laboratories Canada?
What are Frontage's expansion plans in Canada?
Who will Dr. Abdul Mutlib report to at Frontage Holdings?
What experience does Dr. Mutlib bring to Frontage Laboratories Canada?
